
About 90% of RNA molecules in our cells are tRNAs. To date, we have mostly been blind to their abundance and regulation in single-cell sequencing. Today, I’m excited to share a new manuscript from my MD/PhD work biorxiv.org/content/10.64898…
✓Developing computational approaches to studying metabolism in cancer, find our publications here: scholar.google.com/citations…

About 90% of RNA molecules in our cells are tRNAs. To date, we have mostly been blind to their abundance and regulation in single-cell sequencing. Today, I’m excited to share a new manuscript from my MD/PhD work biorxiv.org/content/10.64898…

One of the major fascinations of my career thus far is understanding why the immune system fails to control or eliminate some immunogenic cancers. Cancer dormancy brings this question into sharp clinical focus: why do some cancers treated with curative intent come back years or decades after treatment? What role does the immune system play in keeping residual cancer cells from growing in the meantime, why aren’t residual cells eliminated, and what allows them to grow again? We put together a review on immune evasion in cancer dormancy and metastatic reactivation—now out in @trendscancer — with @GizemEfePhD @LuthriaKaran and with thanks to @BizarMd for the opportunity to write on this important topic. There’s been a lot of progress in understanding how the immune system controls metastatic outgrowth, how dormant cancer cells escape elimination, and how inflammation can allow them to reawaken. But most of what we know mechanistically comes from mouse models. Studying this in patients is difficult. The cells are rare, scattered across tissues, and clinically silent. Finding them is hard; figuring out what they’re doing and how they interact with surrounding immune cells is harder. We discuss what we’ve learned and approaches that could help us study these processes directly in patients. Understanding this biology is essential if we want to prevent late metastatic relapse. I think this deserves more attention and research investment. authors.elsevier.com/c/1o5RM…

Adding new T-REx data to my plot of muscle loss vs weight loss from GLP1RAs. Still no convincing evidence that they cause disproportionate muscle loss.

Our bodies are colonized by trillions of viruses that we live with in homeostasis. The most diverse and abundant of these viral families are anelloviruses. A new paper from us at @MSKCancerCenter explores what happens after we *all* have been infected biorxiv.org/content/10.64898… 1/n

Happy to report a rigorously controlled, comprehensively characterized mouse model in which cachexia is driven specifically by lung metastases, paired with a genetically identical, non-cachectic control group. Hope cachexia researchers find it useful. biorxiv.org/content/10.64898…

MitImpact 4: a genome-wide resource for the interpretation of coding and non-coding mitochondrial DNA variants academic.oup.com/nar/advance…

Faculty ad is out, please help spread the word Come #DreamBig together, without a doubt, in the best city in the world! jobs.sciencecareers.org/job/…

I'm very happy to share the final version of our paper, “MCT1-dependent mitochondrial lactate import sustains cardiac metabolism,” out in Nature! We show how lactate fuels heart mitochondria and helps protect the heart during stress. nature.com/articles/s41586-0… @UofUBiochem 1/10

Incredible study just published in @NatureMedicine by @EdReznik, @CentralParkWMD and colleagues at @MSKCancerCenter on one of the most important and least appreciated topics in oncology, the wasting of muscle and fat that drives weight loss in cancer patients, known as cachexia. Overall, they found a hazard ratio of ~3, meaning cancer patients with cachectic weight loss have TRIPLE the risk of death. Can counteracting cachexia help keep patients alive? This question is personal for me. In 2015 I lost a dear friend Alan Sonnenfeld to pancreatic cancer with cachexia. In 2018, my @Immuneering $IMRX colleagues and I presented data at AACR supporting the development of a MEK inhibitor with optimized pharmacokinetics to treat cachexia. We subsequently developed a third-generation MEK inhibitor, atebimetinib, designed to both reduce tumor volume and preserve body mass. This week atebimetinib was featured on the cover of Cancer Research, and a few weeks ago we presented data at the AACR Conference on Pancreatic Cancer showing how atebimetinib both reduced tumor volume and preserved body mass in pancreatic cancer patients treated in our Phase 2 study. Atebimetinib is now in Phase 3. @pfizer also deserves credit for developing ponsegromab for cancer cachexia, but beyond the two of us there is far too little effort in this area. In fact, companies rarely even report weight changes on their clinical trials. Hopefully @EdReznik's important publication will bring more attention to a topic that could make a big difference in keeping cancer patients alive! Dr. Reznik's Paper: nature.com/articles/s41591-0… Our 2018 Abstract: aacrjournals.org/cancerres/a… Our Cancer Research Paper: aacrjournals.org/cancerres/a… Our AACR Conference on Pancreatic Cancer Data: immuneering.com/wp-content/u… Key Ponsegromab Paper: nejm.org/doi/abs/10.1056/NEJ…

Researchers at MSK and their collaborators are gaining new insights into cancer cachexia, a wasting syndrome that affects nearly half of all patients. Findings in @NatureMedicine could help predict which patients are most at risk and help facilitate timely support and interventions. Learn more: bit.ly/4yhYfl3

Finally, thank you to @CancerGrand and the CANCAN team, especially @MarcusDGon @JanowitzTobias and @EileenWhitePhD who continually open my eyes to new and exciting avenues for inquiry into cachexia and tumor-host biology.

If you're interested in coming with my lab on this journey that brings quantitative and computational biology as close to day-to-day medicine as we can manage, apply for a postdoc here msk.wd108.myworkdayjobs.com/…




What do you do with this data? We now have predictive, calibrated models for risk of cachexia in several cancer types. As new therapies and interventions for cachexia are trialed, these can be used to power enrollment and identify those at highest need for early intervention